« Return to News | Technology Solutions

Taigle becomes SAFE-BioPharma partner

Thursday, October 20, 2011 01:21 PM

Taigle has become a vendor partner of SAFE-BioPharma, the non-profit that manages the SAFE-BioPharma digital identity and signature standard for the biopharmaceutical and healthcare industries. The SAFE-BioPharma standard allows its member companies to meet security and confidentiality needs specific to the life sciences.

Taigle provides seamless and fully integrated software solutions to companies in the healthcare, financial services, media and entertainment, and other industries. The company’s MySignatureBook service, which allows people with interoperable digital identities to access and apply digital signatures to documents in the cloud, is being used by the National Cancer Institute, Bristol-Myers Squibb, and Sanofi-Aventis in their cloud-based research collaboration.  

SAFE-BioPharma digital identities are interoperable with US government regulatory and other agencies and with other organizations across the life sciences and other industries.

“As a SAFE-BioPharma vendor partner we will be closer to the growing global community of companies and other organizations that use the standard to improve their operations,” said Ajit Sodhi, president, Taigle. “We are committed to helping members verify and manage digital identities and to apply SAFE-BioPharma digital signatures.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.